Adding Niraparib to Standard Treatment May Slow Cancer Growth for Some Patients With Metastatic Castration-Sensitive Prostate Cancer

ASCO Perspective Quote

“This trial emphasizes the importance of germline and somatic testing in patients with metastatic prostate cancer at the time of diagnosis; homologous recombination repair mutations have been identified in up to 25% of patients with metastatic disease and this study shows that early intervention with a PARP inhibitor may improve outcomes. While the combinations of novel hormone therapies and PARP inhibitors have already shown to improve outcomes in the castrate-resistant setting, this is the first trial to show that the addition of a PARP inhibitor to abiraterone may have a role in the hormone-sensitive setting in those with homologous recombination repair deficient prostate cancer,” said Bradley McGregor, MD, Director of Clinical Research for the Lank Center of Genitourinary Oncology at Dana-Farber Cancer Institute and an ASCO Expert in genitourinary cancers.

Study at-a-Glance 

CHICAGO — Results from the international phase 3 AMPLITUDE clinical trial found that adding niraparib to abiraterone acetate (AKEEGA™) plus prednisone (AAP) can help slow cancer growth for people with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene alterations. These results build on findings from the previous MAGNITUDE study, which led to the U.S. Food and Drug Administration (FDA) approval of niraparib with AAP for HRR-altered mCRPC. The research will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago.  

About the Study

“Metastatic castration-sensitive prostate cancer is a heterogeneous disease with diverse responses to therapies. Although a combination of androgen receptor pathway inhibitors has improved survival in patients with this diagnosis, certain genomic alterations, such as those in the HRR pathway, confer poor prognosis. Therefore, there is still a need for treatments that are tailored to patients whose tumors harbor HRR alterations,” said lead study author Gerhardt Attard, MD, PhD, FRCP, Cancer Institute, University College London, London, United Kingdom.

Approximately 1 in 4 people with mCSPC have alterations in the HRR genes. Examples of HRR genes include BRCA1, BRCA2, CHEK2, and PALB2. Research has shown that people with mCSPC with HRR gene alterations have reduced survival chances, and most patients with mCSPC will eventually develop mCRPC. By definition, mCSPC is earlier-stage disease where the cancer is still sensitive to hormone therapy, while mCRPC is more advanced as the cancer becomes resistant to these therapies. People with mCRPC often have a poor prognosis and a poor response to treatment.  

Previous results from the MAGNITUDE clinical trial showed that treatment with the PARP inhibitor niraparib combined with AAP helped slow cancer growth in people with mCRPC with HRR gene alterations. These findings led the FDA to approve niraparib with AAP for these patients in 2023. In the AMPLITUDE clinical trial, researchers wanted to learn if the same benefits of niraparib could be seen in people with mCSPC. 

The study enrolled 696 patients with mCSPC with either germline or somatic HRR gene alterations. The median age of patients in the study was 68 years old. The patients had received no more than 6 months of treatment with androgen deprivation therapy (ADT). Eligible patients could have also received 6 or fewer cycles of docetaxel and/or treatment with AAP for 45 days or fewer if their metastatic cancer had spread outside the lymph nodes.  

The patients were randomly assigned to receive either niraparib with AAP (348 patients) or AAP with a placebo (348 patients). Of the patients, more than half (55.6%) had alterations in the BRCA1 or BRCA2 genes. Most of the patients also had tumors with aggressive features, such as cancer that had spread to the lymph nodes or was already at an advanced stage at the time of diagnosis. 

Key Findings 

At a median follow-up of just over 2.5 years (30.8 months), the researchers found that:

• Niraparib significantly improved radiographic progression-free survival (rPFS) compared to the placebo. In the patients who received niraparib, the median rPFS was not met, while the patients who received a placebo had a median rPFS of 29.5 months.  
• Overall, niraparib reduced the risk of cancer growth by 37% compared to AAP alone in all patients and by 48% in the subgroup of patients with BRCA1 or BRCA2 mutations.
• The time until symptoms got worse was longer for patients who received niraparib compared to those who received a placebo.  
• Researchers observed a trend toward improved overall survival in the niraparib group. However, these data were still immature, as they did not yet meet the criteria for statistical significance. 

Serious side effects were more common in the niraparib group. In this group, 75.2% of patients experienced serious or life-threatening side effects compared to 58.9% of those in the placebo group. The most common serious side effects were anemia and hypertension. More patients in the niraparib group also discontinued treatment due to side effects (15% vs. 10% in the placebo group). 

Next Steps

Future research will focus on exploring niraparib with AAP earlier in disease evolution. Researchers will also continue to study niraparib with AAP given in combination with other drugs that have complementary mechanisms of action for prostate cancer at different stages. 

This study was funded by Janssen Research & Development, LLC.

View author disclosures  

View the abstract

View the News Planning Team disclosures

Het abstract is dit:

Phase 3 AMPLITUDE trial: Niraparib (NIRA) and abiraterone acetate plus prednisone (AAP) for metastatic castration-sensitive prostate cancer (mCSPC) patients (pts) with alterations in homologous recombination repair (HRR) genes.